About Harmony Biosciences Holdings, Inc. 
Harmony Biosciences Holdings, Inc.
Pharmaceuticals & Biotechnology
Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders living with medical needs. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. Narcolepsy is a chronic, debilitating neurologic disorder of sleep-wake state instability. The Company’s product, WAKIX (pitolisant), is a molecule with an action, designed to histamine signaling in the brain by binding to H3 receptors.
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 74 Schemes (40.3%)
Foreign Institutions
Held by 123 Foreign Institutions (9.38%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
No Data
Revenue and Profits:
Net Sales:
200 Million
(Quarterly Results - Jun 2025)
Net Profit:
40 Million
Pharmaceuticals & Biotechnology
USD 2,061 Million (Small Cap)
13.00
NA
0.00%
-0.46
23.40%
2.67






